We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gamma Medica-Ideas Installs FLEX™ Pre-Clinical Imaging System
News

Gamma Medica-Ideas Installs FLEX™ Pre-Clinical Imaging System

Gamma Medica-Ideas Installs FLEX™ Pre-Clinical Imaging System
News

Gamma Medica-Ideas Installs FLEX™ Pre-Clinical Imaging System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gamma Medica-Ideas Installs FLEX™ Pre-Clinical Imaging System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gamma Medica-Ideas has announced the installation of one of its FLEX™ Pre-Clinical Imaging Systems at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.

The dual modality SPECT/CT system will be used in the laboratory of Dr. Juri G. Gelovani, Chairman of the Department of Experimental Diagnostic Imaging at M.D. Anderson.

His research is focused on developing approaches to molecular imaging that will help detect cancer earlier and enable care teams to assess the extent of the disease sooner, making a significant impact on the diagnosis, therapy, and management of cancer.

"The advantages of multi-modality imaging instruments are widely recognized in the radiological molecular imaging community. The FLEX Pre-Clinical Imaging System is very reliable and provides high resolution SPECT images that are very accurately fused with corresponding CT images," said Dr. Gelovani.

"We will use the system in the pre-clinical phase of development of novel radiolabeled agents for imaging tumor-specific biomarkers for tumor detection and selection of effective therapies, for monitoring of treatment response, for biodistribution studies of novel radiolabeled tumor-targeted drugs, and for imaging genetic and cellular therapies of cancer."

“M.D. Anderson is one of the leading medical institutions in the world,” said David W. Wilk, Gamma Medica’s Senior Vice President of Sales.

“We are pleased that Dr. Gelovani has chosen our FLEX Pre-Clinical system to help him pursue his cutting-edge research.”

Advertisement